MedTrace Logo

Calcitonin in the Treatment of Fibromyalgia

NCT00754884 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2015-12-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether nasal administration of salmon calcitonin is effective and safe in the treatment of symptoms and signs of primary fibromyalgia.

Conditions

  • Fibromyalgia

Interventions

DRUG

salmon calcitonin

daily intranasal 200 U.I. salmon calcitonin for periods of 14 days at a time

DRUG

intranasal saline solution plus glycerol

daily intranasal (one shot) saline solution plus glycerol for a period of 14 days

Sponsors & Collaborators

  • Unidad de Investigacion en Enfermedades Cronico-Degenerativas

    lead OTHER

Principal Investigators

  • Cesar R. Ramos-Remus, M.D., MSc · Attending Rheumatologist HGR45 and Director UIECD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00754884 on ClinicalTrials.gov